

| Type | L # | Hits | Search Text   | DBs                                | Time Stamp          | Comments | Error Definitors |
|------|-----|------|---|------------------------------------|---------------------|----------|------------------|
| 1    | BRS | L1   | 3383<br>(insulin-like adj growth adj factor-1) or IGF-I   | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:10 |          | 0                |
| 2    | BRS | L2   | 8<br>(composition same ((insulin-like adj growth adj factor-1) or adj growth adj factor-1) or IGF-I) same solubilizing                            | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:10 |          | 0                |
| 3    | BRS | L3   | 28<br>(composition same ((insulin-like adj growth adj factor-1) or adj growth adj factor-1) or IGF-I) same (arginine or guanidinium or guanidine) | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:11 |          | 0                |
| 4    | BRS | L4   | 747<br>"12" adj mg/ml   | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:12 |          | 0                |
| 5    | BRS | L5   | 16728<br>pH adj 5.5   | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:12 |          | 0                |
| 6    | BRS | L6   | 60028<br>arginine or (guanidine adj hydrochloride) or N-acetyl-arginine or guanidinium  | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:13 |          | 0                |
| 7    | BRS | L7   | 501<br>solubilizing adj compound  | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27<br>16:14 |          | 0                |

| Type | L # | Hits | Search Text   | DBs                                | Time Stamp       | Comments | Error Definitors |
|------|-----|------|---|------------------------------------|------------------|----------|------------------|
| 8    | BRS | L8   | 2260 "200" adj mg/ml  | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:17 |          | 0                |
| 9    | BRS | L9   | 7 ( 2 or 3 ) same 5   | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:50 |          | 0                |
| 10   | BRS | L10  | 3 ( 2 or 3 ) same pH same mg/ml   | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:48 |          | 0                |
| 11   | BRS | L11  | 261839 (glutaric adj acid) or (maleic adj acid) or (succinic adj acid) or (citric adj acid) or imidazole or histidine | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:49 |          | 0                |
| 12   | BRS | L12  | 18573 11 same buffer  | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:50 |          | 0                |
| 13   | BRS | L13  | 2 ( 2 or 3 ) same pH same 12  | USPAT; US-PGPUB; EPO; JPO; DERWENT | 2004/01/27 16:50 |          | 0                |

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I  
L2 3034 S COMPOSITION (P) L1  
L3 73 S SOLUBILIZING COMPOUND  
L4 368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
L5 1 S L2 (P) L4 (P) SOLUBILIZING  
L6 1 S L2 (P) L3  
L7 0 S L6 NOT L5  
L8 0 S L2 (P) PH (P) MG/ML  
L9 1 S BUFFER (P) PH (P) L2  
L10 1 S L9 NOT L5  
L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID)OR (SUCCINIC ACID) OR (CITRIC  
L12 11680 S L11 (P) BUFFER  
L13 1 S L2 (P) L12  
L14 1 S L13 NOT L9  
L15 0 S L14 NOT L5  
L16 328 S SHIRLEY B?/AU  
L17 40 S BAJWA K?/AU  
L18 2 S (L16 OR L17) AND L2  
L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> log y

FILE 'MEDLINE' ENTERED AT 17:13:39 ON 27 JAN 2004

FILE 'CAPLUS' ENTERED AT 17:13:39 ON 27 JAN 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 17:13:39 ON 27 JAN 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 17:13:39 ON 27 JAN 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 17:13:39 ON 27 JAN 2004

COPYRIGHT 2004 THOMSON ISI

FILE 'AGRICOLA' ENTERED AT 17:13:39 ON 27 JAN 2004

=> s (insulin-like growth factor-1 or IGF-I

UNMATCHED LEFT PARENTHESIS '(INSULIN-LI'

The number of right parentheses in a query must be equal to the  
number of left parentheses.

=> s (insulin-like growth factor-1) or IGF-I

5 FILES SEARCHED...

L1 86011 (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I

=> s composition (p) l1

L2 3034 COMPOSITION (P) L1

=> s solubilizing compound

L3 73 SOLUBILIZING COMPOUND

=> s arginine or (guanidine hydrochloride) or N-acetyl-arginine or guanidinium

L4 368475 ARGinine OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
GUANIDINIUM

=> s l2 (p) l4 (p) solubilizing

L5 1 L2 (P) L4 (P) SOLUBILIZING

=> d l5 1 ibib abs

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325815 CAPLUS

DOCUMENT NUMBER: 130:343031

TITLE: Compositions providing for increased IGF-I solubility

INVENTOR(S): Shirley, Bret A.; Bajwa, Kamaljit

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO.   | KIND | DATE     | APPLICATION NO. | DATE     |
|--|------|----------|-----------------|----------|
| WO 9924063   | A1   | 19990520 | WO 1998-US23673 | 19981106 |
| W: AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,<br>CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU,<br>ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,<br>MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,<br>SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,<br>BY, KG, KZ, MD, RU, TJ, TM |      |          |                 |          |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,<br>CM, GA, GN, GW, ML, MR, NE, SN, TD, TG   |      |          |                 |          |
| AU 9915193   | A1   | 19990531 | AU 1999-15193   | 19981106 |
| EP 1028748   | A1   | 20000823 | EP 1998-959383  | 19981106 |
| EP 1028748   | B1   | 20030502 |                 |          |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

JP 2001522814 T2 20011120 JP 2000-520151 19981106  
AT 238807 E 20030515 AT 1998-959383 19981106

PRIORITY APPLN. INFO.: US 1997-64891P P 19971107  
WO 1998-US23673 W 19981106

AB IGF-I compns. include a solubilizing compd. comprising a guanidinium group that provides for IGF-I compns. in which IGF-I is highly sol. at pHs of about 5.5 or greater and at refrigerated temps. IGF-I was formulated with arginine for injection.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I  
L2 3034 S COMPOSITION (P) L1  
L3 73 S SOLUBILIZING COMPOUND  
L4 368475 S ARGinine OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR  
L5 1 S L2 (P) L4 (P) SOLUBILIZING

=> s l2 (p) l3

L6 1 L2 (P) L3

=> s l6 not l5

L7 0 L6 NOT L5

=> s l2 (p) pH (p) mg/ml

'ML' IS NOT A VALID FIELD CODE

L8 0 L2 (P) PH (P) MG/ML

=> s buffer (p) ph (p) l2

L9 1 BUFFER (P) PH (P) L2

=> s l9 not l5

L10 1 L9 NOT L5

=> d l10 1 ibib abs

L10 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:124031 CAPLUS

DOCUMENT NUMBER: 128:188629

TITLE: Composition comprising insulin and insulin-like growth factor-I (IGF-I)

INVENTOR(S): Clark, Ross G.; Oeswein, James Q.; Yeung, Douglas A.

PATENT ASSIGNEE(S): Genentech, Inc., USA

SOURCE: PCT Int. Appl., 56 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO.  | KIND | DATE            | APPLICATION NO.  | DATE     |
|---|------|-----------------|------------------|----------|
| WO 9806423  | A1   | 19980219        | WO 1997-US13566  | 19970731 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,<br>DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,<br>LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,<br>PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,<br>VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |      |                 |                  |          |
| RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,<br>GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,<br>GN, ML, MR, NE, SN, TD, TG  |      |                 |                  |          |
| US 5783556  | A    | 19980721        | US 1996-696314   | 19960813 |
| ZA 9706598  | A    | 19990217        | ZA 1997-6598     | 19970724 |
| CA 2261799  | AA   | 19980219        | CA 1997-2261799  | 19970731 |
| AU 9738243  | A1   | 19980306        | AU 1997-38243    | 19970731 |
| AU 731745   | B2   | 20010405        |                  |          |
| EP 918536   | A1   | 19990602        | EP 1997-935259   | 19970731 |
| EP 918536   | B1   | 20010919        |                  |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO  |      |                 |                  |          |
| JP 2000516229   | T2   | 20001205        | JP 1998-509799   | 19970731 |
| EP 1114644  | A1   | 20010711        | EP 2001-106315   | 19970731 |
| EP 1114644  | B1   | 20020814        |                  |          |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, SI, LT, LV, FI, RO  |      |                 |                  |          |
| AT 205722   | E    | 20011015        | AT 1997-935259   | 19970731 |
| ES 2162321  | T3   | 20011216        | ES 1997-935259   | 19970731 |
| PT 918536   | T    | 20020328        | PT 1997-97935259 | 19970731 |
| AT 222120   | E    | 20020815        | AT 2001-106315   | 19970731 |
| PT 1114644  | T    | 20021231        | PT 2001-1106315  | 19970731 |
| ES 2180523  | T3   | 20030216        | ES 2001-106315   | 19970731 |
| AU 752411   | B2   | 20020919        | AU 2000-72263    | 20001214 |
| PRIORITY APPLN. INFO.:  |      | US 1996-696314  | A 19960813       |          |
|   |      | EP 1997-935259  | A3 19970731      |          |
|   |      | WO 1997-US13566 | W 19970731       |          |

AB Formulations contg. NPH insulin are useful for treating hyperglycemic disorders, such as diabetes, in a mammal in need of treatment. One such formulation, which is preferably administered parenterally, more preferably by injection, comprises IGF-I and NPH insulin, in amts. of from or about 1 to 10 mg IGF-I and from or about 0.2 to 2 mg NPH insulin in a pharmaceutically acceptable carrier. Another such formulation comprises IGF-I and NPH insulin in an acetic acid salt buffer. Still another formulation comprises IGF-I and NPH insulin in a wt. ratio of NPH insulin to IGF-I of from or about 10:1 to 1:50 (wt./wt.), from or about 0.05 to 0.3 M of an osmolyte, from or about 0.1 to 10 mg/mL of a stabilizer, and from or about 5 to 100 mM of a buffer at from or about pH 5 to 7. A still further compn. comprises NPH insulin in an acetic acid salt buffer.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> his

HIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s (glutaric acid) or (maleic acid)or (succinic acid) or (citric acid) or imidazole or histidine

3 FILES SEARCHED...

5 FILES SEARCHED...

L11 450482 (GLUTARIC ACID) OR (MALEIC ACID) OR (SUCCINIC ACID) OR (CITRIC ACID) OR IMIDAZOLE OR HISTIDINE

=> s l11 (p) buffer

L12 11680 L11 (P) BUFFER

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 17:13:39 ON 27 JAN 2004

L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I

L2 3034 S COMPOSITION (P) L1

L3 73 S SOLUBILIZING COMPOUND

L4 368475 S ARGinine OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR

L5 1 S L2 (P) L4 (P) SOLUBILIZING

L6 1 S L2 (P) L3

L7 0 S L6 NOT L5

L8 0 S L2 (P) PH (P) MG/ML

L9 1 S BUFFER (P) PH (P) L2

L10 1 S L9 NOT L5

L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID)OR (SUCCINIC ACID) OR (CITRIC

L12 11680 S L11 (P) BUFFER

=> s l2 (p) l12

L13 1 L2 (P) L12

=> s l13 not l9

L14 1 L13 NOT L9

=> s l14 not l5

L15 0 L14 NOT L5

=> s shirley b?/au

L16 328 SHIRLEY B?/AU

=> s bajwa k?/au

L17 40 BAJWA K?/AU

=> s (l16 or l17) and l2

L18 2 (L16 OR L17) AND L2

=> duplicate remove l18

PROCESSING COMPLETED FOR L18

L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> d l18 1-2 ibib abs

L18 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325815 CAPLUS

DOCUMENT NUMBER: 130:343031

TITLE: Compositions providing for increased IGF-I solubility

INVENTOR(S): Shirley, Bret A.; Bajwa, Kamaljit

PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO.             | KIND   | DATE  | APPLICATION NO. | DATE       |
|------------------------|--|---|-----------------|------------|
| WO 9924063             | A1   | 19990520  | WO 1998-US23673 | 19981106   |
|                        | W:   | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,<br>CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU,<br>ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,<br>MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,<br>SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,<br>BY, KG, KZ, MD, RU, TJ, TM |                 |            |
|                        | RW:  | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,<br>FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,<br>CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  |                 |            |
| AU 9915193             | A1   | 19990531  | AU 1999-15193   | 19981106   |
| EP 1028748             | A1   | 20000823  | EP 1998-959383  | 19981106   |
| EP 1028748             | B1   | 20030502  |                 |            |
|                        | R:   | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,<br>IE, FI   |                 |            |
| JP 2001522814          | T2   | 20011120  | JP 2000-520151  | 19981106   |
| AT 238807              | E  | 20030515  | AT 1998-959383  | 19981106   |
| PRIORITY APPLN. INFO.: |  |   | US 1997-64891P  | P 19971107 |
|                        |  |   | WO 1998-US23673 | W 19981106 |
| AB                     | IGF-I compns. include a solubilizing compd. comprising a guanidinium<br>group that provides for IGF-I compns. in which IGF-I is highly |   |                 |            |

sol. at pHs of about 5.5 or greater and at refrigerated temps. IGF-I was formulated with arginine for injection.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:325814 CAPLUS  
DOCUMENT NUMBER: 130:343030  
TITLE: Human IGF-I syrup composition and its use  
INVENTOR(S): Shirley, Bret A.; Hora, Maninder S.  
PATENT ASSIGNEE(S): Chiron Corporation, USA  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

| PATENT NO.             | KIND | DATE   | APPLICATION NO. | DATE       |
|------------------------|------|--|-----------------|------------|
| WO 9924062             | A1   | 19990520   | WO 1998-US23672 | 19981106   |
|                        | W:   | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM |                 |            |
|                        | RW:  | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG   |                 |            |
| AU 9913847             | A1   | 19990531   | AU 1999-13847   | 19981106   |
| EP 1028747             | A1   | 20000823   | EP 1998-957637  | 19981106   |
|                        | R:   | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI   |                 |            |
| JP 2001522813          | T2   | 20011120   | JP 2000-520150  | 19981106   |
| US 2003109427          | A1   | 20030612   | US 1998-187661  | 19981106   |
| PRIORITY APPLN. INFO.: |      |  | US 1997-64891P  | P 19971107 |
|                        |      |  | US 1998-96081P  | P 19980811 |
|                        |      |  | WO 1998-US23672 | W 19981106 |

AB A highly concd., low salt-contg., biol. active syrup form of IGF-I or variant thereof and methods for its prepn. are provided. This novel syrup form of IGF-I has an IGF-I concn. of at least about 250 mg/mL, a d. of about 1.0 g/mL to about 1.2 g/mL, and a viscosity of about 13,000 cP (cps) to about 19,000 cps, as measured at ambient temp. (23 °C). The IGF-I syrup is prepd. by pptg. or partitioning IGF-I from soln., preferably by adjusting the soln. pH or by use of a soly. enhancer to conc. IGF-I in soln. followed by removal of the soly. enhancer. The pptd. syrup is useful as a means of storing IGF-I in a stable form and as a means of prepg. compns. comprising biol. active IGF-I. Pharmaceutical compns. and kits comprising this concd. IGF-I syrup are provided. The pptd. IGF-I syrup, IGF-I reconstituted from the IGF-I syrup, pharmaceutical compns., and kits are useful in IGF-I therapy directed to IGF-I-responsive conditions.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:12:44 ON 27 JAN 2004)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT  
17:13:39 ON 27 JAN 2004

- L1 86011 S (INSULIN-LIKE GROWTH FACTOR-1) OR IGF-I
- L2 3034 S COMPOSITION (P) L1
- L3 73 S SOLUBILIZING COMPOUND
- L4 368475 S ARGININE OR (GUANIDINE HYDROCHLORIDE) OR N-ACETYL-ARGININE OR
- L5 1 S L2 (P) L4 (P) SOLUBILIZING
- L6 1 S L2 (P) L3
- L7 0 S L6 NOT L5
- L8 0 S L2 (P) PH (P) MG/ML
- L9 1 S BUFFER (P) PH (P) L2
- L10 1 S L9 NOT L5
- L11 450482 S (GLUTARIC ACID) OR (MALEIC ACID)OR (SUCCINIC ACID) OR (CITRIC
- L12 11680 S L11 (P) BUFFER
- L13 1 S L2 (P) L12
- L14 1 S L13 NOT L9
- L15 0 S L14 NOT L5
- L16 328 S SHIRLEY B?/AU
- L17 40 S BAJWA K?/AU
- L18 2 S (L16 OR L17) AND L2
- L19 2 DUPLICATE REMOVE L18 (0 DUPLICATES REMOVED)

=> log y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST  | 90.67            | 91.09         |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|--|------------------|---------------|
| CA SUBSCRIBER PRICE                        | -2.77            | -2.77         |

STN INTERNATIONAL LOGOFF AT 17:24:44 ON 27 JAN 2004